Apellis Pharmaceuticals (NASDAQ:APLS) PT Lowered to $38.00 at Mizuho

Apellis Pharmaceuticals (NASDAQ:APLS) had its price objective lowered by research analysts at Mizuho from $39.00 to $38.00 in a report issued on Thursday, Benzinga reports. The firm presently has a “neutral” rating on the stock. Mizuho’s target price indicates a potential upside of 40.85% from the stock’s previous close.

A number of other brokerages also recently issued reports on APLS. William Blair initiated coverage on shares of Apellis Pharmaceuticals in a research report on Wednesday, October 16th. They set an “outperform” rating for the company. Wells Fargo & Company reduced their price target on Apellis Pharmaceuticals from $47.00 to $43.00 and set an “equal weight” rating for the company in a research report on Tuesday, September 24th. UBS Group lowered their price objective on Apellis Pharmaceuticals from $85.00 to $83.00 and set a “buy” rating on the stock in a research report on Friday, August 9th. Jefferies Financial Group reissued a “buy” rating and issued a $80.00 target price on shares of Apellis Pharmaceuticals in a report on Wednesday, July 31st. Finally, Robert W. Baird lowered their price target on shares of Apellis Pharmaceuticals from $96.00 to $92.00 and set an “outperform” rating on the stock in a report on Monday, September 23rd. Four research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $67.94.

Apellis Pharmaceuticals Trading Down 2.2 %

Shares of NASDAQ:APLS opened at $26.98 on Thursday. Apellis Pharmaceuticals has a 1 year low of $26.28 and a 1 year high of $73.80. The stock’s fifty day moving average price is $33.63 and its 200-day moving average price is $38.89. The company has a market cap of $3.27 billion, a P/E ratio of -7.80 and a beta of 0.87. The company has a debt-to-equity ratio of 1.73, a current ratio of 5.08 and a quick ratio of 4.18.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earnings results on Thursday, August 1st. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.03. Apellis Pharmaceuticals had a negative net margin of 52.99% and a negative return on equity of 138.32%. The firm had revenue of $199.70 million for the quarter, compared to the consensus estimate of $190.89 million. During the same quarter last year, the firm posted ($1.02) EPS. The business’s quarterly revenue was up 110.2% compared to the same quarter last year. Sell-side analysts expect that Apellis Pharmaceuticals will post -1.37 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director A. Sinclair Dunlop sold 37,000 shares of Apellis Pharmaceuticals stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $36.23, for a total transaction of $1,340,510.00. Following the completion of the transaction, the director now directly owns 100,000 shares of the company’s stock, valued at approximately $3,623,000. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 6.80% of the stock is owned by insiders.

Institutional Trading of Apellis Pharmaceuticals

A number of large investors have recently modified their holdings of the company. Future Financial Wealth Managment LLC bought a new position in Apellis Pharmaceuticals during the 1st quarter worth about $29,000. BI Asset Management Fondsmaeglerselskab A S bought a new position in shares of Apellis Pharmaceuticals during the first quarter valued at approximately $89,000. nVerses Capital LLC increased its holdings in Apellis Pharmaceuticals by 300.0% during the second quarter. nVerses Capital LLC now owns 2,800 shares of the company’s stock valued at $107,000 after buying an additional 2,100 shares during the period. Russell Investments Group Ltd. raised its stake in Apellis Pharmaceuticals by 1,300.8% in the first quarter. Russell Investments Group Ltd. now owns 3,586 shares of the company’s stock worth $211,000 after buying an additional 3,330 shares in the last quarter. Finally, CWM LLC lifted its holdings in Apellis Pharmaceuticals by 299.9% during the second quarter. CWM LLC now owns 4,151 shares of the company’s stock worth $159,000 after buying an additional 3,113 shares during the period. Hedge funds and other institutional investors own 96.29% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).